These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 26255860)

  • 1. Mesoporous silica-based dosage forms improve release characteristics of poorly soluble drugs: case example fenofibrate.
    Dressman JB; Herbert E; Wieber A; Birk G; Saal C; Lubda D
    J Pharm Pharmacol; 2016 May; 68(5):634-45. PubMed ID: 26255860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate.
    O'Shea JP; Nagarsekar K; Wieber A; Witt V; Herbert E; O'Driscoll CM; Saal C; Lubda D; Griffin BT; Dressman JB
    J Pharm Pharmacol; 2017 Oct; 69(10):1284-1292. PubMed ID: 28631822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vivo Performance of Fenofibrate Formulated With Ordered Mesoporous Silica Versus 2-Marketed Formulations: A Comparative Bioavailability Study in Beagle Dogs.
    Bukara K; Schueller L; Rosier J; Daems T; Verheyden L; Eelen S; Martens JA; Van den Mooter G; Bugarski B; Kiekens F
    J Pharm Sci; 2016 Aug; 105(8):2381-5. PubMed ID: 27364460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fast dissolution of poorly water soluble drugs from fluidized bed coated nanocomposites: Impact of carrier size.
    Azad M; Moreno J; Bilgili E; Davé R
    Int J Pharm; 2016 Nov; 513(1-2):319-331. PubMed ID: 27639622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica.
    Van Speybroeck M; Mellaerts R; Mols R; Thi TD; Martens JA; Van Humbeeck J; Annaert P; Van den Mooter G; Augustijns P
    Eur J Pharm Sci; 2010 Dec; 41(5):623-30. PubMed ID: 20850527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel core-shell dual-mesoporous silica nanoparticles for the production of high bioavailable controlled-release fenofibrate tablets.
    Zhao Z; Gao Y; Wu C; Hao Y; Zhao Y; Xu J
    Drug Dev Ind Pharm; 2016; 42(2):199-208. PubMed ID: 26114553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods.
    Hong S; Shen S; Tan DC; Ng WK; Liu X; Chia LS; Irwan AW; Tan R; Nowak SA; Marsh K; Gokhale R
    Drug Deliv; 2016; 23(1):316-27. PubMed ID: 24853963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide.
    Sanganwar GP; Gupta RB
    Int J Pharm; 2008 Aug; 360(1-2):213-8. PubMed ID: 18550302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing the Solubility of Fenofibrate by Nanocrystal Formation and Encapsulation.
    Kumar R; Siril PF
    AAPS PharmSciTech; 2018 Jan; 19(1):284-292. PubMed ID: 28702816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of mixtures of polymeric carriers for dissolution enhancement of fenofibrate using hot-melt extrusion.
    Kalivoda A; Fischbach M; Kleinebudde P
    Int J Pharm; 2012 Jun; 429(1-2):58-68. PubMed ID: 22440149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced oral delivery of celecoxib via the development of a supersaturable amorphous formulation utilising mesoporous silica and co-loaded HPMCAS.
    Lainé AL; Price D; Davis J; Roberts D; Hudson R; Back K; Bungay P; Flanagan N
    Int J Pharm; 2016 Oct; 512(1):118-125. PubMed ID: 27543354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supersaturation of zafirlukast in fasted and fed state intestinal media with and without precipitation inhibitors.
    Madsen CM; Boyd B; Rades T; Müllertz A
    Eur J Pharm Sci; 2016 Aug; 91():31-9. PubMed ID: 27260089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
    O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
    Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5.
    Janssens S; de Armas HN; Roberts CJ; Van den Mooter G
    J Pharm Sci; 2008 Jun; 97(6):2110-20. PubMed ID: 17847067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.
    Li-Hong W; Xin C; Hui X; Li-Li Z; Jing H; Mei-Juan Z; Jie L; Yi L; Jin-Wen L; Wei Z; Gang C
    Int J Pharm; 2013 Sep; 454(1):135-42. PubMed ID: 23871738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of a discriminant and biorelevant in vitro dissolution test for the development of fenofibrate self-emulsifying lipid-based formulations.
    Pestieau A; Krier F; Brouwers A; Streel B; Evrard B
    Eur J Pharm Sci; 2016 Sep; 92():212-9. PubMed ID: 27169683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate.
    Jia Z; Lin P; Xiang Y; Wang X; Wang J; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2011 Sep; 79(1):126-34. PubMed ID: 21658449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles.
    Juenemann D; Jantratid E; Wagner C; Reppas C; Vertzoni M; Dressman JB
    Eur J Pharm Biopharm; 2011 Feb; 77(2):257-64. PubMed ID: 21074611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impregnation of Fenofibrate on mesoporous silica using supercritical carbon dioxide.
    Bouledjouidja A; Masmoudi Y; Van Speybroeck M; Schueller L; Badens E
    Int J Pharm; 2016 Feb; 499(1-2):1-9. PubMed ID: 26732521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.